

Botanix Overview

November 2018

Key investment highlights

Botanix is a global **dermatology company** delivering **synthetic cannabinoids topically** for the treatment of skin diseases



**Dermatology
focused**

Advanced clinical programs targeting multi-billion dollar prescription markets for **acne, atopic dermatitis and psoriasis**



**De-risked drug
active**

Products use a synthetic form of cannabidiol with a proven safety profile (Epidiolex® recently approved by FDA) – **increases the probability of success**



Clinical stage

Successful clinical data from acne and atopic dermatitis patient studies shows industry leading performance, after only 4 weeks of treatment



**Novel
approach**

Novel skin delivery technology, **Permetrex™** - **enhances delivery of cannabidiol into the skin** compared to traditional formulation approaches








**Experienced
team**

Predominantly US based leadership team with **20+ FDA approvals** between them and extensive dermatology industry experience

Clinical programs with near term milestones

Phase 2 acne and atopic dermatitis programs supported by exciting development pipeline, with Permetrex™ collaborations to augment revenue and news flow

Product candidate		Indication	Pre-clin	Ph 1	Ph 1b	Ph 2	Next milestones
Synthetic cannabidiol	BTX 1503	Moderate to severe acne					Phase 2 clinical study underway
	BTX 1204	Atopic dermatitis					Phase 2 clinical study pending
	BTX 1308	Psoriasis					Phase 1b patient study underway
	BTX 1801	Antimicrobial					Phase 1b patient study
Permetrex™ programs	Internal/external	Various					Ongoing Service fees and potential licenses

Experienced team

Global team with proven experience in dermatology and a track record of securing drug approvals



Mr Matthew Callahan
Founder and Board Executive Director



Corporate + IP

- Developed **3 products to date that have received FDA approval, 1 pending approval**
- Ex-investment director of 2 venture capital firms in life sciences
- Serial entrepreneur with extensive produce development and launch experience



Dr Michael Thurn
Head Australian operations



Operations + Regulatory

- Extensive start up life sciences experience across a range of technology platforms
- Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A\$700m



Dr Stephane Levy
Chief Medical Officer



Medical + Clinical

- Ex-CMO of Almirall US operations and VP Sanofi and Novartis
- Broad commercial and clinical development experience



Ms Jillian Chapas Reed
Snr Director Clinical Operations



Clinical

- 20 years clinical trial experience across dermatology and immunology
- Held senior director roles with CRO's companies and hospital sponsors



Dr Judith Plon
VP Regulatory Affairs



Regulatory

- 30 years regulatory experience with multiple FDA approved dermatology products
- Ex-AVP Global Regulatory Affairs at Sanofi



Dr Bill Bosch
Executive Director




Manufacturing + IP

- **6 FDA approved products** and inventor of the iCeutica SoluMatrix Technology
- Founder of NanoSystems and co-inventor of drug delivery technology NanoCrystal

Cannabinoid research interest is exploding

Cannabinoids are attracting strong interest as their efficacy and safety profiles are validated in clinical studies and the recent FDA approval of Epidiolex® (GW Pharma)

Cannabidiol (CBD)



- One of ~ 113 cannabinoids identified in the *cannabis sativa* plant
- Accounts for **up to 40% of natural plant extract**
- **Not psychoactive or addictive** – does not convert to THC *in vivo*
- **Broad mechanism of action** - including immune modulation, anti-inflammatory effects and anti-microbial activity
- Substantial human safety database published

Significant clinical trial interest


A screenshot of the ClinicalTrials.gov website showing search results for Cannabidiol. The page header includes the NIH U.S. National Library of Medicine logo and the text "ClinicalTrials.gov". There are links for "Find Studies" and "About Studies". Below the header, there is a search bar with the text "Home > Search Results". There are links for "Modify Search" and "Start Over". A purple oval highlights the text "148 Studies found for: Cannabidiol".

- 38 Epilepsy
- 17 Multiple Sclerosis
- 15 Pain
- 9 Schizophrenia
- 6 Cancer
- 63 Other

Only 1 trial in dermatology (Botanix)

Permetrex™ skin delivery technology


Proprietary Permetrex™ technology delivers high doses of drug into the layers of the skin without use of permeation enhancers, preservatives, or the use of irritating alcohol/petrolatum additives



Botanix holds the exclusive rights to utilise Permetrex™ for all drugs that treat skin diseases

Permetrex™ technology enables superior delivery of cannabidiol

Permetrex™ delivers more much more cannabidiol (CBD) into the target layers of the skin, even though the CBD concentration of the BTX 1503 formulation is only ¼ to ½ the concentration of alternative formulations



1. Botanix Pharmaceuticals data on file

Development Pipeline

BTX 1503: acne

BTX 1204: atopic dermatitis


BTX 1308: psoriasis

BTX 1801: antimicrobial

BTX 1503: acne – mechanism of action for acne

BTX 1503 is a safe and well tolerated topical treatment that addresses all 3 key pathologies of acne

Inflammatory mechanisms involved in different stages of acne¹



CBD has been shown to...


- ✓ Have **anti-inflammatory** effects on human **sebocytes** and to **suppress sebocyte proliferation**²
- ✓ Have **potent anti-microbial** activity against gram-positive bacteria³
- ✓ **Inhibit human keratinocyte proliferation**, through a non CB1/CB2 mechanism⁴

1. Rocha & Bagatin Acne Vulgaris: an Inflammatory Disease Even Before the Onset of Clinical Lesions (2014). *Inflammation and Allergy – Drug Targets* June 13(3); 2. Olah et al. *J Clin Invest.* 2014;124(9):3713-3724; 3. Appendino et al. *J Natl Prod.* 2008;71:1427-1430; 4. Wilkinson & Williamson. *J Derm Sci.* 2007;45:87-92.

BTX 1503: acne – outperforms leading acne products



4 week study data shows a marked reduction in inflammatory lesions, greater than any other FDA approved topical acne product ¹

Lesion count reduction (%)



* Day 35 results indicates the reduction effect persists 7 days after the last treatment

Comparison with other FDA approved products


Product	Owner	Lesion count reduction (%) ²	2016 annual revenue ³
<div>Epiduo®</div>  <ul style="list-style-type: none"> Combination of two drugs – benzoyl peroxide and adapalene ✗ Common side effects include redness, skin peeling mild burning / stinging and dryness 	Galderma	~42%	US\$494m
<div>Aczone®</div>  <ul style="list-style-type: none"> ✓ Few side effects ✗ Studies showed large placebo / vehicle effect – i.e. at 12 weeks Aczone reduced inflammatory lesions by 54% while vehicle achieved 48% reduction 	Allergan	~38%	US\$456m
BTX 1503	Botanix	~47%	-

1. Botanix Pharmaceuticals data on file. 2. Lesion count reduction based on average inflammatory lesion reduction at 4 weeks. 3. Based on 2016 annual revenue in the US.

New data supporting anti-inflammatory effects of cannabidiol


Newly processed images from the Phase 1b acne patient study, demonstrate a clear anti-inflammatory effect over the 4 week treatment course¹

Baseline (Day 1)



Nose not treated

Visit 4 (4 weeks)



Nose not treated

BTX 1503: acne – Phase 2 study overview

12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne

Design

- 5 dose groups: ~360 subjects
 - High Dose twice a day: ~90 subjects
 - High Dose once a day: ~90 subjects
 - Low Dose once a day: ~90 subjects
 - Vehicle/Control: ~90 subjects
- ~28 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate to severe acne patients
- Treatment Period 12 weeks

Endpoints

- Primary endpoints:
 - absolute change from Baseline to Week 12 in inflammatory lesions
- Secondary endpoints:
 - absolute change from Baseline to Week 12 in non-inflammatory lesions
 - % change from Baseline to Week 12 in inflammatory and non-inflammatory lesions
 - proportion of patients with at least 2 grade reduction from Baseline IGA at week 12
- Safety
 - adverse events and local tolerability

Commenced July 2018 (~12 months duration) – fully funded

BTX 1503: acne – next steps

Botanix is pursuing a rapid clinical development strategy to accelerate product commercialisation and timing to first revenues

- Phase 2 clinical study started early 3Q CY2018 and will take approximately 12 months to complete
- Study designed to deliver data that allows licensing and other corporate opportunities

BTX 1503 indicative clinical timeline (CY)


File IND for FDA regulated Phase 2 trial

First patient enrolled in Phase 2 trial

US and Australian sites all activated


Patient enrolment complete

★ Milestones



BTX 1204: atopic dermatitis – mechanism of action

Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin



1. During the “acute phase”, dendritic cells cause excessive **Th2 and Th17** cell activation
2. During the “chronic phase”, dendritic cells recruit **Th1** cell populations that release **Interferon- γ**

CBD inhibits Th17 responses (IL17), anti-inflammatory effect (*in vitro* model of IL-17A-induced mucosal inflammation using human cells)^{1, 2}

CBD attenuates Th2 responses (IL4/IL13), anti-inflammatory effect (*in mouse models of AD*)^{3, 4}

CBD inhibits Interferon- γ production which prevents deterioration of skin barrier function (*In activated lymphocyte cultures*)¹ (*mouse model of autoimmune myocarditis*)⁵

1. Harvey et al. *Cytokine*. 2014;65:236-244; 2. Kaplan et al. *Biochem Pharmacol*. 2008;76(6):726-737; 3. Gaffal et al. *Exp Derm*. 2014;23:401-406; 4. Kim et al. *Int J Derm*. 2015;54:e410-e408; 5. Lee et al. *Mol Med*. 2016;22:136-146.

BTX 1204: atopic dermatitis – Phase 1b study design

Successful 4-week treatment period, double-blind, vehicle controlled patient study concluded in late May 2018

Design

- ~36 subjects 18 years and older (24 active / 12 vehicle)
- 4 Australian dermatology sites
- BTX 1204 solution BID applied topically
- At least 1 lesion (25 to 200 cm²), on the trunk upper or lower extremities
- Signs of AD score ≥ 6 and ≤ 12
- Investigator's Static Global Assessment (ISGA) of mild (2) or moderate (3)

Endpoints

- Primary endpoints:
 - safety – AEs, labs, local tolerability and signs of atopic dermatitis
- Exploratory endpoints:
 - ISGA
 - target lesion size




Study successfully completed end Q2 CY2018

BTX 1204: atopic dermatitis – Phase 1b study results

BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of AD¹

Treatment success (%)²



Key takeaways

Efficacy still increasing at 4 week timepoint

- Achieved treatment success similar to many competitive topical products at the end of their peak treatment period
- Data suggests longer treatment period for BTX 1204 possible for increased efficacy, potentially to exceed industry performance

Clear separation from vehicle (placebo)

- Despite being a small study, BTX 1204 shows superiority over vehicle, starting at early time points
- First vehicle-controlled study for Botanix, which also supports potential for other pipeline products

Excellent safety profile

- Safety and tolerability established with no burning, stinging or application site adverse events
- BTX 1204 profile allows extended dosing which remains a key challenge with most available therapies

1. Botanix data on file. Results indicated substantial reduction in key signs of AD, providing confidence that unmet needs in AD can be addressed

2. Treatment success defined as a greater than, or equal to, a 4 point improvement in the signs and symptoms of AD

BTX 1204: atopic dermatitis – Phase 2 study design

12 week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate AD

Design

- 2 dose groups: ~200 subjects
 - BTX 1204: ~100 subjects
 - Vehicle/Control: ~100 subjects
- ~25 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate AD patients
- Treatment period of 12 weeks

Endpoints

- Primary endpoint:
 - proportion of subjects with ISGA success defined as an ISGA score of “Clear” (0) or “Almost Clear” (1) with at least a 2 grade improvement from Baseline at Week 12
- Secondary endpoints:
 - change from Baseline in the Signs of AD
 - % body surface area (BSA) affected by AD
 - time to achieve IGA success
- Safety
 - adverse events and local tolerability


First patients in Q4 CY2018 – fully funded

BTX 1204: atopic dermatitis – next steps

BTX 1204 complements existing products in development, allowing faster development and transition times through key regulators (FDA and DEA)

- development program leverages existing data from BTX 1503 acne studies, lowering regulatory and safety hurdles
- common usage of DEA licensed dermatology clinics in US from BTX 1503 acne Phase 2 study, reduces cost and start-up timing

BTX 1204 indicative clinical timeline (CY)



★ Milestones



BTX 1308: psoriasis – overview

Development pipeline also includes other synthetic cannabidiol and Permetrex™ enabled products targeting key dermatology markets

BTX 1308: psoriasis

- **Target market:** ~7.5m Americans have psoriasis (note: most have plaque psoriasis)
- **Market size:** estimated annual costs of injectable biologic treatments in the US is ~US\$20bn p.a.
- **Current issues:** biologic drugs are expensive and have serious side effect issues
- **Unmet needs:** safe and effective topical product for mild to moderate psoriasis



Psoriasis

Phase 1b study commenced November CY2018 – fully funded



BTX 1308 leverages prior data from:



- ✓ BTX 1503 acne clinical program
 - ✓ BTX 1204 AD clinical program
 - ✓ Permetrex™ technology clinical studies
- ➔ Minimal development pathway

BTX 1308: psoriasis – next steps

Botanix has commenced a Phase 1b study to test BTX 1308 against vehicle and a marketed psoriasis drug in patients

- Novel multi-drug comparison study format in the *same patient*, provides high quality data on BTX 1308 efficacy
- Biopsy data will elucidate MOA and (for the first time) confirm anti-inflammatory and immune modulation activity
- Study de-risks psoriasis indication, as well as provides scientific support to mechanisms for acne and atopic dermatitis

BTX 1801 indicative development timeline (CY)




Bioskin GmbH psoriasis plaque test, including change in infiltrate thickness as measured by sonography


BTX 1801: antimicrobial – the problem of antimicrobial resistance

More than 700,000 people die as a result of antimicrobial resistance globally every year and estimates predict that by 2050, 10m lives p.a. will be at risk. However, no new classes of antibiotics have been approved in 33+ years

Deaths attributable to antimicrobial resistance (AMR)¹



Number of antibiotic classes discovered or patented²




1. Tackling Drug Resistant Infections Globally Final Report and Recommendations (2016), The Review on Antimicrobial Resistance
2. Pew Charitable Trusts; Deak et al. Progress in the Fight Against Multidrug Resistant Bacteria?; A Review of FDA Approved Antibiotics 2010-2015. 31 May 2016. DOI: 10.7326/M16-0291

BTX 1801: antimicrobial – results summary

BTX 1801 data demonstrates potential for a new antimicrobial to treat unmet needs in skin infections together with additional benefits seen in prior Botanix studies (e.g. reduction in inflammation)

Summary of data



The study results demonstrate that the delivery of cannabidiol with Permetrex™ can reduce the concentration of the active drug required to achieve the highest levels of bacterial killing

BTX 1801 may have the following benefits


- ✓ Gram-positive bactericidal effect
- ✓ New mechanism of action
- ✓ Active against MRSA
- ✓ Topical application suited for skin infections
- ✓ Benign side effect profile based on previous clinical studies
- ✓ Ability to use long term
- ✓ Anti-inflammatory and skin barrier improvement properties
- ✓ Suitable for treatment of children (due to low toxicity)
- ✓ Prevent early use of IV antibiotics (significant side effects)

Key catalysts

Significant clinical and operational milestones across multiple programs expected over the next 12 months

Indicative activities and milestones

BTX 1503 Acne Phase 2	First patient enrolled in Phase 2 study
	Patient enrolment complete
	Phase 2 multi-centre acne patient clinical study
BTX 1204 Atopic dermatitis Phase 2	Pre-IND Meeting for Phase 2 study
	First Patients Phase 2 study
	Phase 2 multi-centre AD patient clinical study
BX 1308 Psoriasis Phase 1b	Phase 1b study in psoriasis patients
BTX 1801 Antimicrobial	Identification of skin disease indication
	Collaboration with University of Queensland
Permetrex™	Research collaborations and partnership discussions



★ Milestones

Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Contact us

Matt Callahan

Botanix Pharmaceuticals

Founder and Board Executive Director

P: +1 215 767 4184

E: mcallahan@botanixpharma.com

Visit us

www.botanixpharma.com

Follow us on social media



Botanix Pharmaceuticals Limited (ASX:BOT)

